Literature DB >> 15183057

HIV-1 acute infection env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity.

Frédéric Reynard1, Ahmed Fatmi, Bernard Verrier, Frédéric Bedin.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) envelope protein (Env) has evolved to limit its overall immunogenicity by extensive glycosylation. Only a few studies dealing with glycosylation sites have taken into account available 3D data in a global approach. We compared primary env sequences from patients with acute HIV-1 infection. Conserved N-glycosylation sites were placed on the gp120-3D model. Based on vicinity, we defined glycosylation clusters. According to these clusters, we engineered plasmids encoding deglycosylated gp160 mutants. We also constructed mutants corresponding to nonclustered glycans or to the full deglycosylation of the V1 or V2 loop. After in vitro expression, mutants were tested for functionality. We also compared the inhibition of pseudotyped particles infection by human-neutralizing sera. Generally, clustered and nonclustered mutants were affected similarly. Silencing of more than one glycan had deleterious effects, independently of the type of sugar removed. However, some mutants were moderately affected by glycans removal suggesting a distinct role for these N-glycans. Additionally, compared to the wild-type pseudovirus, two of these mutants were neutralized at higher sera dilutions strengthening the importance of the location of specific N-glycans in limiting the neutralizing response. These results could guide the selection of env mutants with the fewest antigenic and functional alterations but with enhanced neutralization sensitivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183057     DOI: 10.1016/j.virol.2004.03.022

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Authors:  Rajnish Kumar; Michael Tuen; Hualin Li; Doris B Tse; Catarina E Hioe
Journal:  Vaccine       Date:  2011-09-23       Impact factor: 3.641

2.  Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.

Authors:  Samantha Townsley; Yun Li; Yury Kozyrev; Brad Cleveland; Shiu-Lok Hu
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

3.  N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03.

Authors:  Wenbo Wang; Brett Zirkle; Jianhui Nie; Jian Ma; Kai Gao; Xiaojiang S Chen; Weijing Huang; Wei Kong; Youchun Wang
Journal:  J Acquir Immune Defic Syndr       Date:  2015-07-01       Impact factor: 3.731

4.  Influence of N-linked glycosylation of porcine reproductive and respiratory syndrome virus GP5 on virus infectivity, antigenicity, and ability to induce neutralizing antibodies.

Authors:  Israrul H Ansari; Byungjoon Kwon; Fernando A Osorio; Asit K Pattnaik
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

5.  Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine.

Authors:  Rajnish Kumar; Maria Luisa Visciano; Hualin Li; Catarina Hioe
Journal:  J AIDS Clin Res       Date:  2012-03-09

6.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

Review 7.  Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Authors:  Michael Vaine; Shan Lu; Shixia Wang
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

8.  The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity.

Authors:  Nicholas M Provine; Wendy Blay Puryear; Xueling Wu; Julie Overbaugh; Nancy L Haigwood
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

9.  Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.

Authors:  Wendy M Blay; Theresa Kasprzyk; Lynda Misher; Barbra A Richardson; Nancy L Haigwood
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

10.  Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy.

Authors:  Vladimir A Morozov; Alexei V Morozov; Dirk Schürmann; Dirck Schürmann; Heiko Jessen; Claudia Kücherer
Journal:  Virus Genes       Date:  2007-04-18       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.